Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 10—October 2018

Candida auris in Healthcare Facilities, New York, USA, 2013–2017

Eleanor Adams, Monica Quinn, Sharon Tsay, Eugenie Poirot, Sudha Chaturvedi, Karen Southwick, Jane Greenko, Rafael Fernandez, Alex Kallen, Snigdha Vallabhaneni, Valerie Haley, Brad Hutton, Debra Blog, Emily LutterlohComments to Author , Howard Zucker, and Candida auris Investigation Workgroup1
Author affiliations: New York State Department of Health, New Rochelle, New York, USA (E. Adams, K. Southwick); New York State Department of Health, Albany, New York, USA (M. Quinn, S. Chaturvedi, V. Haley, B. Hutton, D. Blog, E. Lutterloh, H. Zucker); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S. Tsay, E. Poirot, A. Kallen, S. Vallabhaneni); New York City Department of Health and Mental Hygiene, New York, New York, USA (E. Poirot); New York State Department of Health, Central Islip, New York, USA (J. Greenko); New York State Department of Health, New York (R. Fernandez); State University at Albany School of Public Health, Albany, New York, USA (V. Haley, D. Blog, E. Lutterloh)

Main Article

Table 4

Antifungal susceptibility data for first Candida auris isolates from 51 clinical cases, New York, USA, 2013–2017*

Antifungal Tentative resistance breakpoint (16) MIC50 MIC range† No. (%) resistant
Fluconazole >32 >256 8.00 to >256 50 (98)
Itraconazole NA 0.500 0.25–1.00 NA
Voriconazole NA 2.000 0.50–4.00 NA
Posaconazole NA 0.250 0.12–0.50 NA
Isavuconazole NA 0.500 0.25–2.00 NA
Caspofungin >2 0.060 0.03–0.25 0
Micafungin >4 0.120 0.06–0.25 0
Anidulafungin >4 0.250 0.12–0.50 0
Amphotericin B >2 1.500 0.50–4.00 15 (29)
Flucytosine NA 0.125 0.125–0.25 NA

*NA, not available.
†MICs for azoles and echinocandins are defined as the lowest drug concentration that caused 50% growth inhibition compared with the drug-free controls; MICs for amphotericin B and flucytosine are defined as the lowest concentration at which there was 100% growth inhibition. MIC50 was defined as the MIC at which >50% of the isolates of C. auris tested were inhibited.

Main Article

  1. Lee  WG, Shin  JH, Uh  Y, Kang  MG, Kim  SH, Park  KH, et al. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol. 2011;49:313942. DOIPubMedGoogle Scholar
  2. Chowdhary  A, Sharma  C, Duggal  S, Agarwal  K, Prakash  A, Singh  PK, et al. New clonal strain of Candida auris, Delhi, India. Emerg Infect Dis. 2013;19:16703. DOIPubMedGoogle Scholar
  3. Sarma  S, Kumar  N, Sharma  S, Govil  D, Ali  T, Mehta  Y, et al. Candidemia caused by amphotericin B and fluconazole resistant Candida auris. Indian J Med Microbiol. 2013;31:901. DOIPubMedGoogle Scholar
  4. Chowdhary  A, Anil Kumar  V, Sharma  C, Prakash  A, Agarwal  K, Babu  R, et al. Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis. 2014;33:91926. DOIPubMedGoogle Scholar
  5. Magobo  RE, Corcoran  C, Seetharam  S, Govender  NP. Candida auris-associated candidemia, South Africa. Emerg Infect Dis. 2014;20:12501. DOIPubMedGoogle Scholar
  6. Chakrabarti  A, Sood  P, Rudramurthy  SM, Chen  S, Kaur  H, Capoor  M, et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med. 2015;41:28595. DOIPubMedGoogle Scholar
  7. Emara  M, Ahmad  S, Khan  Z, Joseph  L, Al-Obaid  I, Purohit  P, et al. Candida auris candidemia in Kuwait, 2014. Emerg Infect Dis. 2015;21:10912. DOIPubMedGoogle Scholar
  8. Calvo  B, Melo  ASA, Perozo-Mena  A, Hernandez  M, Francisco  EC, Hagen  F, et al. First report of Candida auris in America: Clinical and microbiological aspects of 18 episodes of candidemia. J Infect. 2016;73:36974. DOIPubMedGoogle Scholar
  9. Morales-López  SE, Parra-Giraldo  CM, Ceballos-Garzón  A, Martínez  HP, Rodríguez  GJ, Álvarez-Moreno  CA, et al. Invasive infections with multidrug-resistant yeast Candida auris, Colombia. Emerg Infect Dis. 2017;23:1624. DOIPubMedGoogle Scholar
  10. Schelenz  S, Hagen  F, Rhodes  JL, Abdolrasouli  A, Chowdhary  A, Hall  A, et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control. 2016;5:35. DOIPubMedGoogle Scholar
  11. Vallabhaneni  S, Kallen  A, Tsay  S, Chow  N, Welsh  R, Kerins  J, et al.; MSD. MSD. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus—United States, May 2013–August 2016. MMWR Morb Mortal Wkly Rep. 2016;65:12347. DOIPubMedGoogle Scholar
  12. Ben-Ami  R, Berman  J, Novikov  A, Bash  E, Shachor-Meyouhas  Y, Zakin  S, et al. Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel. Emerg Infect Dis. 2017;23:195203. DOIPubMedGoogle Scholar
  13. Ruiz Gaitán  AC, Moret  A, López Hontangas  JL, Molina  JM, Aleixandre López  AI, Cabezas  AH, et al. Nosocomial fungemia by Candida auris: First four reported cases in continental Europe. Rev Iberoam Micol. 2017;34:237. DOIPubMedGoogle Scholar
  14. Satoh  K, Makimura  K, Hasumi  Y, Nishiyama  Y, Uchida  K, Yamaguchi  H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53:414. DOIPubMedGoogle Scholar
  15. Welsh  RM, Bentz  ML, Shams  A, Houston  H, Lyons  A, Rose  LJ, et al. Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic healthcare surface. J Clin Microbiol. 2017;55:29963005. DOIPubMedGoogle Scholar
  16. Centers for Disease Control and Prevention. Recommendations for identification of Candida auris [cited 2017 Oct 18].
  17. Mizusawa  M, Miller  H, Green  R, Lee  R, Durante  M, Perkins  R, et al. Can multidrug-resistant Candida auris be reliably identified in clinical microbiology laboratories? J Clin Microbiol. 2017;55:63840. DOIPubMedGoogle Scholar
  18. Lockhart  SR, Etienne  KA, Vallabhaneni  S, Farooqi  J, Chowdhary  A, Govender  NP, et al. Simultaneous emergence of multidrug resistant Candida auris on 3 continents confirmed by whole genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;64:13440. DOIPubMedGoogle Scholar
  19. Centers for Disease Control and Prevention. Clinical alert to U.S. healthcare facilities—June 2016. Global emergence of invasive infections caused by the multidrug-resistant yeast Candida auris [cited 2017 Feb 28].
  20. New York State Department of Health. Health advisory: alert to New York State healthcare facilities regarding the global emergence of invasive infections caused by the multidrug-resistant yeast Candida auris [cited 2017 Nov 24].
  21. New York State Department of Health. Health advisory: alert to New York State clinical laboratories: identification and reporting of suspected Candida auris isolates [cited 2017 Nov 24].
  22. Stevenson  LG, Drake  SK, Shea  YR, Zelazny  AM, Murray  PR. Evaluation of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of clinically important yeast species. J Clin Microbiol. 2010;48:34826. DOIPubMedGoogle Scholar
  23. Clinical and Laboratory Standards Institute. M27–S4 reference method for broth dilution antifungal susceptibility testing of yeasts: fourth informational supplement. Wayne (PA): The Institute; 2012.
  24. Leach  L, Zhu  Y, Chaturvedi  S. Development and validation of a real-time PCR assay for rapid detection of Candida auris from surveillance samples. J Clin Microbiol. 2018;56:e0122317.PubMedGoogle Scholar
  25. Tsay  S, Welsh  RM, Adams  EH, Chow  NA, Gade  L, Berkow  EL, et al.; MSD. Notes from the field: ongoing transmission of Candida auris in health care facilities—United States, June 2016–May 2017. MMWR Morb Mortal Wkly Rep. 2017;66:5145. DOIPubMedGoogle Scholar
  26. Okinda  N, Kagotho  E, Castanheira  M, Njuguna  A, Omuse  G, Makau  P, et al. Candidemia at a referral hospital in sub-Saharan Africa: emergence of Candida auris as a major pathogen. Poster presented at: European Congress of Clinical Microbiology and Infectious Diseases; 2014 May 10–13; Barcelona, Spain.
  27. New York State Department of Health. Get the facts about Candida auris [cited 2017 Dec 28].

Main Article

1Additional members of the workgroup are listed at the end of this article.

Page created: September 12, 2018
Page updated: September 12, 2018
Page reviewed: September 12, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.